Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px
Organisation › Details

SpliceBio S.L.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. The Company’s proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. *

 

Period Start 2020-09-15 renamed
  Predecessor ProteoDesign (ES)
Products Industry gene therapy
  Industry 2 adeno-associated viral vector (AAV vector)
Persons Person Vila-Perelló, Miquel (SpliceBio 202009 CEO + Co-Founder)
  Person 2 Caelles, Gerard (SpliceCio 202202 CBO)
     
Region Region Barcelona
  Country Spain (España)
  Street 10 Baldiri Reixac
Parc Científic de Barcelona
  City 08028 Barcelona
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: SpliceBio S.L.. (2/16/22). "Press Release: SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline". Barcelona.
     
   
Record changed: 2024-06-07

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x200px

More documents for SpliceBio S.L.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top